Lack of Evidence of HPV Etiology of Prostate Cancer Following Radical Surgery and Higher Frequency of the Arg/Pro Genotype in Turkish Men with Prostate Cancer

Overview

Journal Int Braz J Urol

Specialty Urology

Date 2017 Jan 27

PMID 28124524

Citations 6

Authors

Merve Aydin

Aliseydi Bozkurt

Aytekin Cikman

Baris Gulhan

Mehmet Karabakan

Aysun Gokce

Murat Alper

Murat Kara

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to assess the possible role of HPV in the development of prostate cancer (PCa) and investigate the distribution of the p53 codon 72 polymorphism in PCa in a Turkish population.

Materials And Methods: A total of 96 tissues, which had been obtained using a radical surgery method, formalin-fixed and parafin-embedded, were used in this study. The study group consisted of 60 PCa tissues (open radical prostatectomy) and the control group contained 36 benign prostatic hyperplasia tissues (BPH) (transvesical open prostatectomy). The presence of HPV and the p53 codon 72 polymorphism was investigated in both groups using real-time PCR and pyrosequencing.

Results: The results of the real-time PCR showed no HPV DNA in any of the 36 BPH tissue samples. HPV-DNA was positive in only 1 of the 60 PCa samples (1.7%). The HPV type of this sample was identified as HPV-57. The distribution of the three genotypes, Arg/Arg, Arg/Pro and Pro/Pro was found to be 45.6, 45.6, and 8.8% in the PCa group and 57.1%, 34.3% and 8.6% in the control group, respectively. Compared with the control group, patients with PCa had a higher frequency of the Arg/Pro genotype and Proline allele (odds ratio (OR)=1.67, 95% confidence interval (CI)=0.68-4.09, p=0.044; OR=1.13, 95% CI=0.76-1.68, p=0.021, respectively).

Conclusions: The results of the study do not support the hyphothesis that prostate cancer is associated with HPV infection but indicated that Proline allele can be a risk factor in the development of PCa in the Turkish population.

Citing Articles

Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures, and serum samples from a Spanish Caucasian population.

Toscano-Guerra E, Maggio V, Garcia J, Semidey M, Celma A, Morote J Front Oncol. 2024; 14:1398411.

PMID: 39193388 PMC: 11347290. DOI: 10.3389/fonc.2024.1398411.

Unveiling the Role of Human Papillomavirus in Urogenital Carcinogenesis a Comprehensive Review.

Karaoglan B, Urun Y Viruses. 2024; 16(5).

PMID: 38793549 PMC: 11125962. DOI: 10.3390/v16050667.

Human papillomavirus and prostate cancer: systematic review and meta-analysis.

Tsydenova I, Ibragimova M, Tsyganov M, Litviakov N Sci Rep. 2023; 13(1):16597.

PMID: 37789036 PMC: 10547781. DOI: 10.1038/s41598-023-43767-7.

Does Human Papillomavirus Play a Causative Role in Prostate Cancer? A Systematic Review Using Bradford Hill's Criteria.

Bello R, Willis-Powell L, James O, Sharma A, Marsh E, Ellis L Cancers (Basel). 2023; 15(15).

PMID: 37568712 PMC: 10416874. DOI: 10.3390/cancers15153897.

Detection of high-risk Human Papillomavirus in prostate cancer from a UK based population.

Ahmed M, Salman N, Sandhu S, Cakir M, Seddon A, Kuehne C Sci Rep. 2023; 13(1):7633.

PMID: 37165210 PMC: 10172334. DOI: 10.1038/s41598-023-34734-3.

References

Epstein J, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P . The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2015; 40(2):244-52. DOI: 10.1097/PAS.0000000000000530. View

Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F . Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998; 393(6682):229-34. DOI: 10.1038/30400. View

Hrbacek J, Urban M, Hamsikova E, Tachezy R, Heracek J . Thirty years of research on infection and prostate cancer: no conclusive evidence for a link. A systematic review. Urol Oncol. 2012; 31(7):951-65. DOI: 10.1016/j.urolonc.2012.01.013. View

Michopoulou V, Derdas S, Symvoulakis E, Mourmouras N, Nomikos A, Delakas D . Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients. Tumour Biol. 2014; 35(12):12765-73. DOI: 10.1007/s13277-014-2604-7. View

Pascale M, Pracella D, Barbazza R, Marongiu B, Roggero E, Bonin S . Is human papillomavirus associated with prostate cancer survival?. Dis Markers. 2013; 35(6):607-13. PMC: 3830784. DOI: 10.1155/2013/735843. View

Chaturvedi A . Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010; 46(4 Suppl):S20-6. DOI: 10.1016/j.jadohealth.2010.01.016. View

Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M . Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 1992; 52(21):5991-6. View

Bergh J, Marklund I, Gustavsson C, Wiklund F, Gronberg H, Allard A . No link between viral findings in the prostate and subsequent cancer development. Br J Cancer. 2006; 96(1):137-9. PMC: 2360195. DOI: 10.1038/sj.bjc.6603480. View

Martinez-Fierro M, Leach R, Gomez-Guerra L, Garza-Guajardo R, Johnson-Pais T, Beuten J . Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer. 2010; 10:326. PMC: 2912861. DOI: 10.1186/1471-2407-10-326. View

10.

Huang S, Wu W, Chang W, Wu M, Chen Y, Chen Y . p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13(12):2217-24. View

11.

Leiros G, Galliano S, Sember M, Kahn T, Schwarz E, Eiguchi K . Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 2005; 5:15. PMC: 1314892. DOI: 10.1186/1471-2490-5-15. View

12.

Pietsch E, Humbey O, Murphy M . Polymorphisms in the p53 pathway. Oncogene. 2006; 25(11):1602-11. DOI: 10.1038/sj.onc.1209367. View

13.

McNicol P, Dodd J . Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J Clin Microbiol. 1990; 28(3):409-12. PMC: 269632. DOI: 10.1128/jcm.28.3.409-412.1990. View

14.

Strickler H, Burk R, Shah K, Viscidi R, Jackson A, Pizza G . A multifaceted study of human papillomavirus and prostate carcinoma. Cancer. 1998; 82(6):1118-25. View

15.

Lu Y, Liu Y, Zeng J, He Y, Peng Q, Deng Y . Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis. Tumour Biol. 2014; 35(5):3997-4005. DOI: 10.1007/s13277-014-1657-y. View

16.

Henner W, Evans A, Hough K, Harris E, Lowe B, Beer T . Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 2001; 49(4):263-6. DOI: 10.1002/pros.10021. View

17.

Chen A, Waterboer T, Keleher A, Morrison B, Jindal S, McMillan D . Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients. Pathol Oncol Res. 2011; 17(3):613-7. DOI: 10.1007/s12253-010-9357-4. View

18.

Munger K, Baldwin A, Edwards K, Hayakawa H, Nguyen C, Owens M . Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004; 78(21):11451-60. PMC: 523272. DOI: 10.1128/JVI.78.21.11451-11460.2004. View

19.

Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

20.

Aghakhani A, Hamkar R, Parvin M, Ghavami N, Nadri M, Pakfetrat A . The role of human papillomavirus infection in prostate carcinoma. Scand J Infect Dis. 2010; 43(1):64-9. DOI: 10.3109/00365548.2010.502904. View